|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.64 USD | -3.02% |
|
-9.16% | +5.67% |
| 06-30 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Company Valuation: Zai Lab Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,059 | 2,946 | 2,688 | 2,853 | 1,962 | 2,159 | - | - |
| Change | - | -51.37% | -8.77% | 6.15% | -31.23% | 10.07% | - | - |
| Enterprise Value (EV) 1 | 4,650 | 1,938 | 1,897 | 2,095 | 1,397 | 1,666 | 1,788 | 1,885 |
| Change | - | -58.33% | -2.13% | 10.47% | -33.34% | 19.29% | 7.33% | 5.43% |
| P/E | -8.29x | -6.63x | -7.9x | -10.1x | -11x | -8.57x | -10.2x | -13.1x |
| PBR | 4.35x | - | 3.34x | 3.36x | 2.73x | 4.1x | 4.59x | 5.14x |
| PEG | - | 0.2x | 0.3x | 0.4x | 0.3x | -0.2x | 0.6x | 0.6x |
| Capitalization / Revenue | 42x | 13.7x | 10.1x | 7.15x | 4.26x | 4.82x | 3.63x | 2.87x |
| EV / Revenue | 32.2x | 9.01x | 7.11x | 5.25x | 3.04x | 3.72x | 3.01x | 2.51x |
| EV / EBITDA | -6.7x | -4.89x | -5.3x | -7.75x | -6.51x | -6.77x | -11x | -24.5x |
| EV / EBIT | -6.64x | -4.79x | -5.17x | -7.43x | -6.09x | -6.39x | -10.2x | -20.6x |
| EV / FCF | -8.19x | -4.94x | -9.23x | -9.5x | -8.5x | -9.47x | -15.4x | -26.8x |
| FCF Yield | -12.2% | -20.2% | -10.8% | -10.5% | -11.8% | -10.6% | -6.48% | -3.73% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.58 | -4.63 | -3.46 | -2.6 | -1.6 | -2.244 | -1.88 | -1.464 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.3 | 215 | 266.7 | 399 | 460.2 | 447.6 | 594.6 | 751.5 |
| EBITDA 1 | -693.6 | -396.1 | -357.5 | -270.3 | -214.4 | -246.2 | -163.3 | -76.84 |
| EBIT 1 | -700.1 | -404.4 | -366.6 | -282.1 | -229.4 | -260.9 | -175.9 | -91.43 |
| Net income 1 | -704.5 | -443.3 | -334.6 | -257.1 | -175.5 | -244.1 | -158.9 | -136.3 |
| Net Debt 1 | -1,409 | -1,008 | -791.3 | -757.9 | -565.3 | -493.5 | -371.4 | -274.2 |
| Reference price 2 | 62.85 | 30.70 | 27.33 | 26.19 | 17.64 | 19.22 | 19.22 | 19.22 |
| Nbr of stocks (in thousands) | 96,409 | 95,972 | 98,349 | 108,937 | 111,219 | 112,355 | - | - |
| Announcement Date | 01/03/22 | 01/03/23 | 27/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.68x | 3.83x | -7.06x | -.--% | 2.16B | |
| 17.35x | 3.71x | 9.57x | 0.59% | 66.74B | |
| 26.36x | 5.45x | 16.03x | 0.6% | 53.32B | |
| 37.26x | 12.6x | 24.05x | -.--% | 48.12B | |
| -42.39x | 3.06x | 9.03x | 3.57% | 38.25B | |
| 25.06x | 3.49x | 11.87x | -.--% | 29.85B | |
| 56.96x | 3.39x | 25.31x | -.--% | 23.51B | |
| -6.24x | 8.61x | -5.3x | -.--% | 21.45B | |
| -37.77x | 18x | -49.29x | -.--% | 16.47B | |
| 24.05x | 5.15x | 13.48x | -.--% | 16.38B | |
| Average | 9.20x | 6.73x | 4.77x | 0.48% | 31.63B | |
| Weighted average by Cap. | 14.04x | 6.39x | 10.20x | 0.66% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ZLAB Stock
- Valuation Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
